YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Myriad Genetics, Inc. SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a c…
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support pr…
The recent update to fair value, from US$3.37 to US$3.91 per share for Myriad Genetics, reflects a recalibration of what analysts think the stock could be worth. This shift sits alongside Street price targets that range widely from US$2 to…
Why Is Myriad Genetics (MYGN) Stock Soaring Today What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin raised the firm's price target on th…
1 Volatile Stock on Our Buy List and 2 We Question A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren't pr…
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how biotechnology stocks…
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:H…
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) an…
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q2. Today, we are lookin…
3 Reasons MYGN is Risky and 1 Stock to Buy Instead Over the past six months, Myriad Genetics's stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. Thi…
Reflecting On Therapeutics Stocks' Q2 Earnings: AbbVie (NYSE:ABBV) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at AbbVie (NYSE:ABBV) and its peers. Over the n…
Key Points Interested in Quest Diagnostics Incorporated? Here are five stocks we like better. Quest Diagnostics is outperforming its growth targets: Revenue increased about 12% and earnings more than 10% in 2025, while 2026 guidance calls…
Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commenta…
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lo…
Myriad Genetics, Inc. SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executi…
2 Unprofitable Stocks to Research Further and 1 We Find Risky Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk…
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:V…
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Over t…
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN) Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next fe…
A month has gone by since the last earnings report for Adma Biologics (ADMA). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading…
A month has gone by since the last earnings report for Harmony Biosciences Holdings, Inc. (HRMY). Shares have added about 12.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next e…
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell…
Why Myriad Genetics (MYGN) Stock Is Down Today What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, stating that m…
Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company’s path to sustainable profitability. Continue Reading
Robinhood upgraded, Uber initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for di…
Myriad Genetics, Inc. SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annua…
Myriad Genetics and Moderna Shares Plummet, What You Need To Know What Happened? A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following th…
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN) As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking…
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,…
Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how biotechnology stocks fared in Q2, startin…
1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses…
3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only ris…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discuss…
Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in un…
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Com…